PBA
CERE

Paradigm Biocapital Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,330,508
Closed -$95.3M – 44
2024
Q2 		$95.3M Hold
2,330,508
– – 3.65% 9
2024
Q1 		$98.5M Hold
2,330,508
– – 3.47% 12
2023
Q4 		$98.8M Sell
2,330,508
-202,464
-8% -$5.82M 4.63% 9
2023
Q3 		$55.3M Buy
2,532,972
+664,026
+36% +$16.6M 3.77% 13
2023
Q2 		$59.4M Buy
1,868,946
+273,747
+17% +$8.4M 4.81% 6
2023
Q1 		$38.9M Buy
+1,595,199
New +$46.8M 3.69% 14

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return